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A chronic increase of oxidative stress is typical of serious pathologies such as myocardial
infarction, stroke, chronic limb ischemia, chronic obstructive pulmonary disease (COPD),
type II-diabetes, age-related macular degeneration leads to an epic increase of morbidity
and mortality in all countries of the world. The initial inflammation followed by an excessive
release of reactive oxygen species (ROS) implies a diffused cellular injury that needs to be
corrected by an inducible expression of the innate detoxifying and antioxidant system. The
transcription factor Nrf2, when properly activated, is able to restore a redox homeostasis
and possibly improve human health.
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INTRODUCTION
Today a considerable fraction of the human population undergoes
excessive feeding while the remaining is either undernourished or
starving. Cardiovascular diseases (Di Paolo et al., 2005), COPD
(Borrelli and Bocci, 2014) type II-diabetes (Feldman, 2003),
smoking, drug addiction and reduced physical activity are situa-
tions widely diffused: the inexorable progression of these diseases
is due to an enhancement of dysmetabolic processes such as
the activation of NADPH-oxidases, xantine oxidase and Toll-
like receptors (Gill et al., 2010) characterized by an excessive
release of both ROS and nitrogen oxidative species (NOS), such
as O−2 , H2O2, OH−, ONOO− which, subjected to Michael addi-
tion reactions with lysine, histidine and cysteine residues lead to
protein carbonylation (Levine, 2002). Moreover hyperglycemia
allows the reaction of the carbonyl group of reducing sugars to
react with free amino groups of hemoglobin to form Schiff-base
intermediates, which undergo the Amadori rearrangements to
damageous ketoamine derivatives. Their degradation into glyoxal
and methylglyoxal allows the formation of inter-intra-molecular
cross-links with long lived proteins to form the AGES. These com-
pounds, deposited in the arterial wall and nerve proteins, switch
on an oxidative stress establishing a vicious inflammatory loops.
These processes lead to insulin resistance in type II-diabetes,
macular and lens degeneration (Li et al., 2009), immune dysfunc-
tion, impaired cell respiration associated to a relevant decline of
antioxidant defenses (Valko et al., 2007). The metabolic dereg-
ulation leads to a further decline of antioxidant proteins and
to a number of metabolic diseases. In the past it was thought
that the administration of several antioxidants may reduce the
damage but this is a passive therapy accompanied by a scarce
bioavailability or inability to reach the appropriate target or to
stimulate the innate antioxidant response (Bocci and Valacchi,
2013). Moreover cytokines such as IL-1, IL-6, IFN gamma, TNF
alpha, via their binding to membrane cell receptors, further trig-
ger ROS production and this situation has been well documented
in ischemia and reperfusion injury, atherosclerosis, rheumatoid
arthritis, pulmonary and neurodegenerative diseases and type
II-diabetes responsible of the death of many millions people.
HOW A CHRONIC OXIDATIVE STRESS CAN BE CORRECTED?
It is now well established that one theory that related the develop-
ment of pathologies (mainly during aging) concerns the progres-
sive cellular loss of functions. One burning question regards the
variability (heterogeneity) of humans to develop diseases, and the
answer can be found in the individual different genetic interac-
tion, environments and life events that shape our body to certain
physiological responses.
Nowadays, the hormesis concept has been revaluated and
stress-induced hormesis may be one effective way to prevent cell
damage and promoting healthy aging. Basically, the term horme-
sis describes a process that results in ameliorating and improve
cellular stress resistance, survival, and longevity in response to
sub-lethal levels of stress. It has been proposed that hormesis can
promote healthy aging. Overall a similar concept described for
the activation of Heat shock Proteins (HSPs) which are as part of
the cell’s internal repair mechanism. Indeed HSPs are also called
“stress-proteins” and respond to several stress not only related
to temperature variation. heat, cold, and oxygen deprivation by
activating several cascade pathways.
Several hormetic stressors have been describe, including, but
not limited to moderate exercise, calorie restriction, pro-oxidant
exposure.
During the last three decades the positive effect of practicing
moderate physical exercise has been deeply studied, confirming
its possible beneficial effect. This concept is based on the fact that
performing exercise requires an increase in ATP production with
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the subsequent increase in metabolism that leads to augment the
cellular ROS production. This phenomena will be able to acti-
vate the cellular defensive mechanisms, in response to increased
ROS levels. This is confirmed by the fact that mild oxidative stress
generated through regular exercise has been associated with a
decreased incidence of ROS-related diseases, such as CDV and
type II diabetes.
The beneficial effect of moderate exercise has become popular
and provided that a moderate exercise, possibly accompanied by
a moderate calorie restriction is performed daily, appears valid
(Kang et al., 2009; Little et al., 2010). While a very intensive
exercise may be detrimental, a moderate exercise induces mito-
chondrial biogenesis and an increased synthesis of super-oxide
dismutase (SOD) and heme-oxygenase-1 (HO-1).
In fact, calorie restriction has an apposite effect, it is able to
slow the metabolism and to reduce ROS production and it has
been strongly inversely correlated to the development of ROS-
related disease. The first studies using laboratory mice kept at a
restricted caloric intake allowed a significant reduction of age-
related diseases and prolonged life. Several studies by Fontana
et al. (2004), Fontana (2008, 2009) in humans showed that long
term calorie restriction is very protective and reduces atheroscle-
rosis and mortality. Nutrient deprivation appears to activate SIRT
1 (Cohen et al., 2004), SIRT 3 (Sack, 2012) and SIRT 6 (Kanfi
et al., 2008, 2012) and promotes a longer survival. The usual calo-
rie intake of 2200–2400 calories/die must be constantly reduced
to about half value and provided that the diet is equilibrated, it
may be accepted by a number of people.
Also diet manipulation has been correlated to decrease the
development of several pathologies. Indeed, administration of
selected chemical compounds may reduce the chronic oxidative
stress.
Recently it has appeared interesting to evaluate the value
of oral curcumin in a dosage of 500mg/day, which, in con-
junction with a daily exercise and dietary reduction, displays
anti-inflammatory and anti-oxidant activity (Gupta et al., 2012).
Unfortunately curcumin has a low bioavailability and remain
uncertain if it is able to reverse the pathology of chronic diseases.
Resveratrol may modulate lifespan and metabolic disorders (Baur
and Sinclaire, 2006). L-sulforaphane (SFN) is an isothiocyanate
found in broccoli able to induce phase II detoxification enzymes
and the synthesis of GSH but once again the dosage able to reverse
a chronic diseases remains uncertain (Finley et al., 2005). There
are also isoflavones, epigallocatechin-3-gallate (EGCG) present in
green tea and finally a dosage of 600–1800mg of N-acetylcysteine
appears useful in pulmonary diseases.
Recently the study of therapeutic gasses such as NO (Knowles
and Moncada, 1992), H2S (Calvert et al., 2009), CO (Pannen
et al., 1998; Nakao et al., 2009), and Hydrogen (Ohsawa et al.,
2007) have become relevant in selected pathologies.
During the last two decades several approaches have been sug-
gested and although the evidences of their beneficial effect are not
yet completely clear, the implementation of these approaches can
be the way to ameliorate their effects on human health.
Besides the above mentioned approaches, other approaches
seems to be involved in the activation of cellular hormetic
process.
Hyperbaric oxygen (HBO) therapy has recently been pro-
moted as an approach to slow aging. HBO treatment consists in
breathing 100% oxygen under increased atmospheric pressure. In
a HBO therapy chamber, the air pressure is increased to three
times higher than normal air pressure. Under these conditions,
the lungs can gather more oxygen than would be possible breath-
ing pure oxygen at normal air pressure. Although the hemoglobin
is saturated, being the blood hyperoxygenated can dissolve oxygen
within the plasma throughout the body. Therefore, the thera-
peutic principle behind HBO stems from increasing the partial
pressure of oxygen in the tissues of the body.
Currently it is used to treat CO poisoning, delayed radiation
injuries, decompression sickness, as well as non-healing diabetic
wounds and others. Furthermore, HBO preconditioning has been
shown to have hormetic effects on stress resistance and can
increase the longevity of C. elegans. Although the mechanism
through which HBO increases longevity is unclear, it is likely to be
related to the fact that HBO can induce low levels of ROS which
are able to induce “mild stress” able itself to trig the transcription
of protective genes.
Similar concept can be applied to the use of ozonether-
apy. Hans Wolff (1927–1980) was the first physician to develop
ozonated autohemotherapy (AHT) by insufflating ex vivo a gas
mixture (O2:95%–O3:5%) into a volume of about 100ml of blood
withdrawn from a patient. Our scientific studies (Bocci, 2006;
Bocci and Aldinucci, 2006; Travagli et al., 2007; Bocci et al.,
2009a,b, 2010, 2011a,b; Sagai and Bocci, 2011) have been useful
to limit the ozone dosage and to fully understand the biologi-
cal mechanisms of action. As ozone is extremely reactive, it must
be used in micrograms. The right concept is that a small acute
oxidative stress will induce a positive antioxidant response by
the patient. Indeed, pharmacologically it acts in a hormetic fash-
ion (Bocci et al., 2011b; Calabrese, 2013) according an inverted
V shape curve. A lower dosage would act as a placebo because
human plasma contains several antioxidants able to neutralize
ozone. The lipoperoxidation of unsaturated fatty acids (PUFA)
with ozone, present in the plasma leads to the formation of alde-
hydes and H2O2 (Pryor et al., 1995), which represent the critical
messengers of ozone. Thus ozone disappears from the plasma
within 1–2min. H2O2 may reach a concentration of a few micro-
grams in plasma because it freely enters into all the blood cells
where activates several biochemical pathways before being totally
reduced to H2O by catalase, thioredoxin and GSH (Antunes and
Cadenas, 2000). H2O2 significantly activates both glycolysis and
glycerophosphomutase in erythrocytes thus increasing the level
of 2,3 diphosphoglycerate (2,3-DPG). This is an important effect
because slowly the oxyhemoglobin curve will be shifted to the
right with the advantage of improving the release of oxygen
into any ischemic tissue (Bocci et al., 2009a). Moreover, leuko-
cytes increase phagocytosis and platelets may release some growth
factors useful in ischemic diseases (Valacchi and Bocci, 1999,
2000).
During the infusion of the ozonated blood the activation of
NO synthase will also expand the oxygenation of ischemic tissues
(Valacchi and Bocci, 2000). In the plasma oxidated antioxidants
such as uric acid will be eliminated as allantoin while ascorbic
acid, thioredoxin and GSH will soon be reduced (Mendiratta
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et al., 1998) thus rapidly restoring the potent antioxidant system
of plasma.
The dogma that ozone should not be used in medicine is
however untenable because human blood, which has a wealth of
antioxidants (about 1.3–1.8mM) is never damaged by the mini-
mal ozone therapeutic concentrations (Bocci et al., 2009a; Bocci
and Valacchi, 2013).
During the infusion of the ozonated blood, the second stress
phase takes place because the hydroperoxides are further broken
down by GSH transferases or lead to the formation of alke-
nals such as 4-HNE (from N6 PUFA) or HHE (from N3 PUFA)
(Long and Picklo, 2010). These alkenals are electrophilic, amphi-
pathic molecules which forms adducts with cysteine, GSH or with
Cys 34 present in the domain 1 of albumin. Moreover alkenals
are metabolized by GSH-transferase, aldehyde dehydrogenase
(Awasthi et al., 2004), and are also excreted via bile (Laurent et al.,
1999) and renal excretion (Alary et al., 1995). The remaining sub-
micromolar concentration of alkenals, bound to the cysteineof
albumin, becomes the second very important messenger as the
adduct will be released in variousorgans of the body and repre-
sents the signal for a variety of cells of a transitory, acute oxidative
stress.
IS THE Keap-Nrf2 PATHWAY ABLE TO STORE A NORMAL
REDOX SYSTEM?
Usually evolution has progressed with the production of oxidative
insults and, whenever possible, the organization of an appropriate
defense system. Unfortunately, during thementioned chronic dis-
eases, orthodox therapy, although effective, is only partially able
to reduce the progressive damage due to the chronic oxidative
stress.
Moi et al. (1994) discovered a new transcription factor denom-
inatedNuclear factor erythroid 2-related (Nrf2) which is a protein
with a molecular weight of 95–110 kilodalton (Lau et al., 2013)
belonging to the basic leucine zipper transcription factor.
Under normal conditions it is repressed by a protein with
624 amino acids called Keap1 (Kelch-like erythoid cell derived
protein) containing as many as 25 cysteines, which is an adap-
tor protein for a Cullin 3 (Cul3)-dependent ubiquitination and
degradation of Nrf2. Normally the complex Nrf2-Keap1 is present
in the cytoplasm with a half-life of about 20min. because, if it is
not used, is degraded by the proteasome. Further on this com-
plex has been examined by several authors (Talalay et al., 1995;
Itoh et al., 1997; Motohashi and Yamamoto, 2004; Jung and Kwak,
2010) and recently the critical role of Nrf2 has become evident.
Suzuki et al. (2013) have clarified the role of Cys151, Cys 273, Cys
288, Cys 226, Cys 613, and of Cys 434. These cysteine residues
are the sensor system and different electrophiles are able to recog-
nize distinct cysteine residues thus making Keap1 a very sensitive
sensor system. As an example SFN binds to Cys151, metals to
Cys 613, 8-nitro-cGMP binds to Cys434 and alkenals select Cys
273 and Cys 288. The blocking of these cysteine causes the loss
of repression of Nrf2 by Keap1 and therefore Nrf2 becomes free
and moves into the nucleus where it dimerizes with members
of the small Maf family and binds to the electrophil response
elements (ARE) located in the regulatory regions of cellular
defense enzyme genes. It has been shown that Nrf2 activation can
be a common denominator among the above mentioned cellu-
lar hermetic activators. In fact the ability of exercise to induce
ROS activates Nrf2, which increase the expression of antioxidant
enzymes, such as GPx, GST, and HO-1 (de Lemos et al., 2012). In
addition in an elegant study, Muthusamy et al. (2012) were able
to show that acute exercise activates Nrf2 in the myocardial tissue
and that disruption of Nrf2 (using KO animals) increases the sus-
ceptibility of myocardial tissue to OS-induced damage, suggesting
that Nrf2 activation could be a potential therapeutic protective
target. In addition, the ability of CR to attenuate vascular oxida-
tive damage seems to be also linked to the activation of Nrf2/ARE
pathway, which may serve as an endogenous vascular antioxidant
system reinforcing the cellular oxidative stress tolerance (Ungvari
et al., 2008).
In line with this, our recent work (Pecorelli et al., 2013) using
endothelial cells has shown that H2O2, 4-HNE and ozonated
human serum show a rapid Nrf2 activation. Other mechanisms
such as the use of butein, the activation of the ERK pathway,
NADPH oxidase 4, accumulation of fumarate causing Keap1 suc-
cination and also phosphorilation of Nrf2 are all able to free Nrf2
(Kensler et al., 2007; Jung and Kwak, 2010; Adam et al., 2011; Yang
et al., 2011, 2012). Finally, the activation of Nrf2 by HBO therapy
has also been also documented in several recent papers (Godman
et al., 2010; Soejima et al., 2012; Xu et al., 2014), therefore on the
whole it is clear that several low intensity or hormetic biologi-
cal stressors can activate the Nrf2 system. The activation of Nrf2
induces an increased synthesis of a number of phase2-proteins
and antioxidant enzymes able to counteract the chronic oxidative
stress as follows:
(1) Activation of the synthesis of antioxidants able to detox-
ify an excess of ROS such as catalase, superoxide-dismutase
(SOD), GSH-peroxidases, GSH-reductase, GSH-transferase,
NADPH-quinone oxidoreductase (NQO1), Cytochrome
P450 monooxygenase system, thioredoxin and thioredoxin
reductase and HSP70.
(2) Activation of the GSH synthase allows a marked increase of
the GSH intracellular level, which is very protective.
(3) The enhancement of the synthesis and levels of phase
II enzymes such as UDP-glucuronosyltransferase,
N-acetyltransferases and sulfotransferases.
(4) The upregulation of HO-1 which is a very protective enzyme
with a possible increase of CO which in combination with
NO allows vasodilation of ischemic tissues.
(5) Reduction of iron overload via elevated ferritin and biliru-
bin as a lipophilic antioxidant. Both the II phase proteins and
the antioxidants are capable to correct the chronic oxidative
stress and to restore a normal redox system.
Nrf2 PARADOX
Paradoxically, recent papers have suggested a dark side of Nrf2
(Wang et al., 2008) that consist in the ability of cancer cells to
acquire a growth advantage thank to the loss of Keap1 leading
therefore to Nrf2 activation. This was confirmed by the fact that
several kind of cell cancer showed a clear Nrf2 up-regulation
(skin, breast, lung, prostate etc. . . ) (Zhang, 2010). Nrf2 over-
expressed provides therefore a clear advantage to cancer cells
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making them less susceptible to OS damage and reinforcing their
chemoresistance. For instance, several phase II enzymes under
Nrf2 control have been overexpressed in cancer cells; HO-1 over-
expression was present in prostate and brain cancer beside renal
cancer (Goodman et al., 1997); NQO1 upregulation was detected
in hepatoblastoma, colon cancer, breast cancer, and non-small cell
lung cancer (Maines and Abrahamsson, 1996).
The reasons behind the overactivation of Nrf2 in cancer cells
are not well clear, although several potential mechanisms have
been proposed such as Keap1 mutation that will accumulate Nrf2
in the nucleus and preventing also its re-uptake (No et al., 2014).
Mutation of Keap1 leads to the overexpression of Nrf2 and
its target genes. Mutation of Keap1 can result in accumulation
of Nrf2 in nucleus through decreased degradation or inhibi-
tion of nuclear export (Gañán-Gómez et al., 2013). In addition
mutation in genes involved in Nrf2 activation such as EGFR,
Myc, etc. . . have been fund in cancer cells (Kim et al., 2010).
Furthermore, epigenetic modification in both Keap1 and Nrf2
can also activate Nrf2 as demonstrated inmalignant glioma, colon
cancer, and breast cancer (Muscarella et al., 2011; Hanada et al.,
2012; Barbano et al., 2013).
CONCLUSIONS
One of the main processes involved in diseases development and
its progression is represented by the alteration of cellular redox
homeostasis. The ability of an organism to reestablish the cor-
rect homeostasis and to faith the increased oxidative levels can be
the critical way to survive and to avoid potential cellular damage.
The activation of Nrf2 by several different mechanisms (calo-
rie restriction, ozonetherapy, HBO, physical exercise) can be a
way to improve life health (Figure 1). In addition, the imple-
mentation of the above mentioned strategies to the conventional
therapies should be new approach to follow to cure several dis-
eases. Of course we need to take into consideration that Nrf2
activation follows an hermetic rule. Constitutively expressed Nrf2
can promote cancer cell proliferation and protect cells against
oxidative stress and therapeutic agents. It must be kept in mind
that chemopreventive agents including various phytochemicals
FIGURE 1 | The use of alternative approaches, such as caloric restriction,
exercise and healthy diet, together with the conventional medical
treatments, could be useful to help patients restore and maintain their
healthy physiological state. The homeostasis between the oxidant and
antioxidant species is frequently perturbed in a number of human
pathological conditions. Hence, the integrative approaches, able to
re-establish the redox balance, could play a key role in restoring the cellular
homeostasis and reduce the side effects of the orthodox medicine.
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can induce chemoresistance and tumor progression by activating
the Keap1-Nrf2 pathway.
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